title: Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients.
abstract: OBJECTIVE
  To assess the relation between beta-blocker use, underlying cardiac risk, and 1-year outcome in vascular surgery patients, including the effect of beta-blocker withdrawal.
  
  
  METHODS
  Prospective survey.
  
  
  METHODS
  711 consecutive peripheral vascular surgery patients from 11 hospitals in the Netherlands between May and December 2004.
  
  
  METHODS
  Patients were evaluated for cardiac risk factors, beta-blocker use and 1-year mortality. Low and high risk was defined according to the Revised Cardiac Risk Index. Propensity scores for the likelihood of beta-blocker use were calculated and regression models were used to study the relation between beta-blocker use and mortality.
  
  
  RESULTS
  285 patients (40%) received beta-blockers throughout the perioperative period (continuous users). Only 52% of the 281 high risk patients received continuous beta-blocker therapy. Beta-blocker therapy was started in 29 and stopped in 21 patients, respectively. One-year mortality was 11%. After adjustment for potential confounders and the propensity of its use, continuous beta-blocker use remained significantly associated with a lower 1-year mortality compared to non-users (HR=0.4; 95%CI=0.2-0.7). In contrast, beta-blocker withdrawal was associated with an increased risk of 1-year mortality compared to non-users (HR=2.7; 95%CI=1.2-5.9).
  
  
  CONCLUSIONS
  We demonstrated an under-use of beta-blockers in vascular surgery patients, even in high-risk patients. Perioperative beta-blocker use was independently associated with a lower risk of 1-year mortality compared to non-use, while perioperative withdrawal of beta-blocker therapy was associated with a higher 1-year mortality.
authors.affiliation: Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands.
authors.forename: S E
authors.initials: SE
authors.lastname: Hoeks
authors.forename: W J M
authors.initials: WJ
authors.lastname: Scholte Op Reimer
authors.forename: H
authors.initials: H
authors.lastname: van Urk
authors.forename: P J G
authors.initials: PJ
authors.lastname: Jörning
authors.forename: E
authors.initials: E
authors.lastname: Boersma
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
authors.forename: J J
authors.initials: JJ
authors.lastname: Bax
authors.forename: D
authors.initials: D
authors.lastname: Poldermans
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D017130:Angioplasty; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004334:Drug Administration Schedule; D004363:Drug Utilization; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D016013:Likelihood Functions; D016015:Logistic Models; D008297:Male; D009426:Netherlands; D016017:Odds Ratio; D019990:Perioperative Care; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000188:drug therapy* / Q000401:mortality* / Q000601:surgery; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures
chemical_list: D000319:Adrenergic beta-Antagonists